Your browser doesn't support javascript.
loading
Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus.
Ocampo-Torres, Mario C; Hernández-Molina, Gabriela; Criales-Vera, Sergio; Sánchez-Guerrero, Jorge; Lara-Reyes, Pilar; Romero-Díaz, Juanita.
Afiliação
  • Ocampo-Torres MC; M.C. Ocampo-Torres, MS, Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Hernández-Molina G; G. Hernández-Molina, MS, Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Criales-Vera S; S. Criales-Vera, MD, Departamento de Radiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
  • Sánchez-Guerrero J; J. Sánchez-Guerrero, PhD, Mount Sinai Hospital, and University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Lara-Reyes P; P. Lara-Reyes, SW, Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Romero-Díaz J; J. Romero-Díaz, MSc, Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, and Department of Internal Medicine, Section of Rheumatology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
J Rheumatol ; 2024 Aug 01.
Article em En | MEDLINE | ID: mdl-38950947
ABSTRACT

OBJECTIVE:

To evaluate the progression of coronary artery calcification (CAC) and associated risk factors in a systemic lupus erythematosus (SLE) cohort.

METHODS:

We reassessed the presence of CAC in patients with SLE who were screened 9 years before, using multidetector computed tomography. Clinical variables (cumulated disease activity and damage accrual), antiphospholipid syndrome and SLE serology, and cardiovascular (CV) risk factors (hypertension, BMI [kg/m2], modified Framingham risk score, lipid profile, menopausal status) were assessed longitudinally.

RESULTS:

We included 104 patients from the parent study. Most of them were women (94.2%), with a mean age of 41.0 (SD 8.3) years and mean disease duration of 14.8 (SD 2.9) years. We documented CAC in 17 patients (16.3%). Seven cases were from the parent study and 10 were incident cases. The cumulative incidence of CAC was 9% and the incidence density was 1 per 100 person-years. CAC occurred more frequently in the age groups 30-39 years and 40-44 years. All patients with previous CAC had worsening of their calcium indexes, and none developed clinical CV events. When comparing prevalent CAC cases (n = 17) vs patients without calcification (n = 87), both groups were similar in traditional CV risk factors, disease duration, Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) area under the curve (AUC), and Systemic Lupus International Collaborating Clinics (SLICC) score, but were more likely to be postmenopausal and have higher apolipoprotein B (apoB) levels. Patients with previous CAC had higher apoB levels, SLEDAI-2K AUC scores, and anticardiolipin IgG antibodies than incident cases.

CONCLUSION:

CAC in patients with SLE progressed over time but was not associated with adverse CV events during the first 9 years of follow-up. ApoB levels and postmenopausal status might be associated with this progression.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article